Abstract
e18532 Background: Cardiovascular (CVS) system disorders in Poland are responsible for 52% of all deaths and 18% loss of DALY (disability-adjusted life year), compared to 38% and 11% in US respectively. A retrospective analysis was performed to investigate whether the high incidence of CVS disorders in Poland would translate into increased mortality related to cardiotoxicity of doxorubicin based chemotherapy regimens. Methods: Patients (N=606) from 7 hematological centers received the average of 6.7 (1-11) chemotherapy cycles, with cumulative dose of doxorubicin 330 mg/m2 (range 25 – 850); 146 (24%) patients were subjected to further treatment (transplant or radiotherapy) as consolidation or in relapse. Initial cardiac assessment was based on medical histories including echocardiography in 340 (56%) cases. All patients or they families were additionally questioned at the time of analysis about symptoms and signs of left ventricular failure (LVF), or the causes of death. Results: Acute cardiotoxicity was reported in 32 (5%) patients: ten of them died (1.6%), chemotherapy had to be postponed, prematurely terminated or the doses reduced in further 22 cases (3.4%0. The average Left Vetricular Ejection Fraction (LVEF), assessed by echochardiography decreased from 62% (range 40-85%) at diagnosis to 56% (range 20-75%) at the end of treatment (p<0.001). Cardiac impairment was significantly less pronounced in 30 patients treated with liposomal doxorubicin (average LVEF 56.4 and 54.7 respectively, p< 0.001). At the average observation time of 3 years, early chronic progressive cardiotoxicity was responsible for 18 cardiac deaths (2.9%) and further 81 patients (13.3%) required cardiological treatment including 22(3%) cases of acute coronary syndromes. At the time of analysis 40 (43%) patients died due to disease progression. Conclusions: In our retrospection CVS disorders are already the second most common cause of mortality in lymphoma patients (28/92 – 30% of all deaths, 28/606 – 4.6% of all cases). With the expected increased incidence of late chronic progressive cardiotoxicity we would estimate cardiac mortality to be at least doubled at 10 years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have